Genelabs' Prestara Phase III Does Not Confirm Bone Mineral Density Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
The trial was designed to meet FDA's "approvable" letter request for confirmation of bone mineral density increases in women with lupus receiving glucocorticoids. Genelabs plans to meet with the agency when it completes data analysis.
You may also be interested in...
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
Genelabs To Meet With FDA Following Positive Open-Label Prestara Study
The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.